# NGR-hTNF in Combination With Standard Chemotherapy to Treat Patients With Advanced Non-small Cell Lung Cancer

> **NCT00994097** · PHASE2 · COMPLETED · sponsor: **AGC Biologics S.p.A.** · enrollment: 121 (actual)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** NGR-hTNF
- **DRUG:** Cisplatin
- **DRUG:** Gemcitabine
- **DRUG:** Pemetrexed

## Key facts

- **NCT ID:** NCT00994097
- **Lead sponsor:** AGC Biologics S.p.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-07
- **Primary completion:** 2017-03
- **Final completion:** 2017-03
- **Target enrollment:** 121 (ACTUAL)
- **Last updated:** 2018-09-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00994097

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00994097, "NGR-hTNF in Combination With Standard Chemotherapy to Treat Patients With Advanced Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00994097. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*